CAMBRIDGE, Mass., Nov. 1, 2024
/PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq:
AKBA), a biopharmaceutical company with the purpose to better the
lives of people impacted by kidney disease, granted three
newly-hired employees options to purchase an aggregate of 20,000
shares of Akebia's common stock on October
31, 2024. The options were granted as an inducement material
to each such employee entering into employment with
Akebia. The options were granted in accordance with Nasdaq
Listing Rule 5635(c)(4).
The options have an exercise price of $1.66 per share, which is equal to the closing
price of Akebia's common stock on the grant date. The stock options
vest over four years, with 25% of the shares vesting on the first
anniversary of the grant date and the remaining 75% of shares
vesting quarterly thereafter, in each case, subject to the new
employee's continued service with Akebia. Each stock option has a
10-year term and is subject to the terms and conditions of Akebia's
inducement award program and a stock option agreement covering the
grant.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated
biopharmaceutical company with the purpose to better the lives of
people impacted by kidney disease. Akebia was founded in 2007 and
is headquartered in Cambridge,
Massachusetts. For more information, please visit our
website at www.akebia.com, which does not form a part of this
release.
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302294414.html
SOURCE Akebia Therapeutics, Inc.
